Poor
Not Aligned
Patient Risk:
Low
Summary
All claims provided are not present in the FDA-approved labeling; none of the extracted patent/generic/market-status statements are supported by the label.
Category Scores
Accurate Statements
Unsupported Statements
The main patent expiries in 2025.
Not supported by FDA labeling.
Some secondary / formulation patents expire in 2026–2027.
Not supported by FDA labeling.
The original 'inhibitor of factor Xa' patents expire in 2025.
Not supported by FDA labeling.
A handful of 'method-of-use' or 'formulation' patents run until 2026–27.
Not supported by FDA labeling.
The SPC expiry is 2025–2026.
Not supported by FDA labeling.
The last SPC version issued was in 2024.
Not supported by FDA labeling.
The EMA-approved SPC is due for re-validation in 2026.
Not supported by FDA labeling.
The expiry of the SPC does not affect patent rights but signals the end of the current product dossier.
Not supported by FDA labeling.
The first generic launch in the EU occurred in 2022 in Spain, France, Italy, and Portugal.
Not supported by FDA labeling.
The first generic launch in the EU occurred in 2023 in Germany.
Not supported by FDA labeling.
Spain: First generic 5 mg tablet launched 1 July 2022 (PharmaGenix).
Not supported by FDA labeling.
France & Italy: Generic 5 mg tablets launched 3 June 2022 (PharmaGenix, plus a second generic by Medica).
Not supported by FDA labeling.
Portugal: 5 mg generic approved 12 May 2022 (by PharmaGenix).
Not supported by FDA labeling.
Germany: First generic 5 mg tablet approved 5 April 2023 (by Medica Pharma).
Not supported by FDA labeling.
Some EU national patent offices applied a patent-term adjustment that short-circuited the remaining patent life for the generic launch in those countries.
Not supported by FDA labeling.
Eliquis' 'method-of-use' patents were not extended beyond the 30-year limit, allowing generic manufacturers to file marketing-authorization applications in 2022.
Not supported by FDA labeling.
Strategic 'early-entry' licensing contributed to earlier generic entry.
Not supported by FDA labeling.
Patents: 2025 (core) → 2026-27 (remaining).
Not supported by FDA labeling.
SPC: Re-validated in 2026 (expires then).
Not supported by FDA labeling.
Generics are already on the market in most EU member states (Spain, France, Italy, Portugal, Germany).
Not supported by FDA labeling.
Generics are usually at a 30-50% price-cut compared with brand-name Eliquis.
Not supported by FDA labeling.
Switching from Eliquis to a generic is generally safe – the generic is bioequivalent.
Not supported by FDA labeling.
However, confirm with a pharmacist or the national drug formulary.
Not supported by FDA labeling.
In most countries generics are the first-line choice, and insurance plans automatically cover the cheaper version.
Not supported by FDA labeling.
If a brand-name manufacturer re-files for a 'new-indication' or 'new-dose-form' patent, that could delay generic entry in a particular country.
Not supported by FDA labeling.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on label alignment; no on-label safety statements were provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about patents, SPCs, generics, and EU market status are not part of FDA labeling.
Suggested Improvement
Limit statements to what is contained in the FDA label; clearly separate label content from external regulatory/market information; avoid patent/generic timelines unless explicitly discussed in labeling or regulatory documents.